The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization

Karasu B., ÇELEBİ A. R. C.

INTERNATIONAL OPHTHALMOLOGY, vol.42, no.9, pp.2729-2740, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 42 Issue: 9
  • Publication Date: 2022
  • Doi Number: 10.1007/s10792-022-02261-1
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Page Numbers: pp.2729-2740
  • Keywords: Choroidal neovascularization, Pathologic myopia, Subfoveal choroidal thickness, Anti-vascular endothelial growth factor agents, OPTICAL COHERENCE TOMOGRAPHY, ANTI-VEGF DRUGS, INTRAVITREAL AFLIBERCEPT, INTRAOCULAR PHARMACOKINETICS, AXIAL LENGTH, RANIBIZUMAB, THICKNESS, BEVACIZUMAB, SECONDARY, THERAPY
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Purpose To evaluate anatomical and visual results of eyes with naive myopic choroidal neovascularization (mCNV) in patients treated with intravitreal anti-vascular endothelial growth factor (VEGF) therapies. Material and methods This is a retrospective, non-randomized, comperative, intervetional study. One hundred fourteen eyes of 114 patients with mCNV who underwent intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR) or intravitreal aflibercept (IVA) monotherapy injections were enrolled into the study. The best corrected visual acuity (BCVA), central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) were compared among the groups during the follow-up periods at the beginning, months 1, 3, 6, 12, and the final visit. Results The mean age of the patients was 47.76 +/- 10.57 years (range, 33-72 years) and the mean follow-up period was 23.34 +/- 6.81 months (range, 13-38 months). The mean BCVA denoted a significantly improve at each group (p < 0.05). In terms of an inter-group analysis of all 3 groups, at months 1, 6, and 12 and final visit, the BCVA were statistically significantly better in the IVA group when compared to both IVB and IVR groups (p = 0.021, p = 0.032, p = 0.024, p = 0.012). There was a significant decrease in CMT following IVB (236.49 +/- 40.91 mu m-190.74 +/- 50.12 mu m), IVA (232.91 +/- 46.29 mu m-193.73 +/- 46.81 mu m) and IVR (234.78 +/- 45.37 mu m-192.21 +/- 37.27 mu m) between baseline and final visit (p = 0.018, p = 0.002, p < 0.001, respectively). There was a statistically significant decrease in SFCT values between baseline and final examination only in the IVA group (p < 0.001). The mean number of injections were 9.18 +/- 3.18 (range; 3 to 13) in IVB, 6.46 +/- 2.93 (range; 3-11) in IVR and 4.45 +/- 1.42 (range; 2-7) in IVA (p = 0.028). Conclusion All three anti-VEGFs were found to be effective in terms of visual results in patients with mCNV. However, we demonstrated that IVA reduces the need for anti-VEGF when compared to patients who received both IVB and IVR. Furthermore, IVA induced a prominent reduction in SFCT, whereas IVR and IVB did not have a significant action on SFCT.